Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Arcus Biosciences (RCUS) Net Income towards Common Stockholders (2017 - 2025)

Historic Net Income towards Common Stockholders for Arcus Biosciences (RCUS) over the last 9 years, with Q3 2025 value amounting to -$135.0 million.

  • Arcus Biosciences' Net Income towards Common Stockholders fell 4673.91% to -$135.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$341.0 million, marking a year-over-year decrease of 2629.63%. This contributed to the annual value of -$283.0 million for FY2024, which is 781.76% up from last year.
  • According to the latest figures from Q3 2025, Arcus Biosciences' Net Income towards Common Stockholders is -$135.0 million, which was down 4673.91% from -$112.0 million recorded in Q1 2025.
  • In the past 5 years, Arcus Biosciences' Net Income towards Common Stockholders registered a high of $279.5 million during Q4 2021, and its lowest value of -$135.0 million during Q3 2025.
  • For the 5-year period, Arcus Biosciences' Net Income towards Common Stockholders averaged around -$58.4 million, with its median value being -$75.5 million (2021).
  • Examining YoY changes over the last 5 years, Arcus Biosciences' Net Income towards Common Stockholders showed a top increase of 63762.48% in 2021 and a maximum decrease of 437963.78% in 2021.
  • Quarter analysis of 5 years shows Arcus Biosciences' Net Income towards Common Stockholders stood at $279.5 million in 2021, then plummeted by 123.97% to -$67.0 million in 2022, then dropped by 20.9% to -$81.0 million in 2023, then fell by 16.05% to -$94.0 million in 2024, then tumbled by 43.62% to -$135.0 million in 2025.
  • Its Net Income towards Common Stockholders stands at -$135.0 million for Q3 2025, versus -$112.0 million for Q1 2025 and -$94.0 million for Q4 2024.